AlphaStocks
5.9
Consider Buy

Prestige Consumer Healthcare Inc. (PBH)

Health Care / Pharmaceuticals

S&P SmallCap 600

$57.66

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

#321out of 1127 in Health Care

Is Prestige Consumer Healthcare Inc. a Good Investment in 2026?

Prestige Consumer Healthcare Inc. (PBH) scores 5.9 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Prestige Consumer Healthcare Inc. as Strong (8/9). The Graham model is the least favorable, rating it Neutral. Prestige Consumer Healthcare Inc. currently trades below its estimated fair value of $86, suggesting potential upside. Prestige Consumer Healthcare Inc. ranks #321 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E13.5ROE11.8Market Cap3B

Estimated Fair Value

$85.6333% below

Fair value above market price. P/E of 13x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

8/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

1% below fair value

Lynch

Attractive

PEG 1.0 · Fast Grower

Greenblatt

Strong

Top 25% (rank 11%)

Frequently Asked Questions

Is Prestige Consumer Healthcare Inc. (PBH) a good investment?
Based on AlphaStocks' composite analysis, Prestige Consumer Healthcare Inc. (PBH) scores 5.9 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Fair value above market price. P/E of 13x is moderate for this quality level.
What is Prestige Consumer Healthcare Inc.'s Piotroski F-Score?
Prestige Consumer Healthcare Inc.'s Piotroski F-Score status is Strong. The raw score is 8/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is PBH overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $86, PBH appears undervalued. The stock currently trades 33% below its estimated fair value. Fair value above market price. P/E of 13x is moderate for this quality level.
How does PBH compare to other Health Care stocks?
Prestige Consumer Healthcare Inc. ranks #321 out of 1127 stocks in the Health Care sector, placing it in the top 28% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about PBH?
AlphaStocks evaluates PBH using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Neutral; Lynch: Attractive; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 5.9/10.

Similar Stocks

PARRFTIAZN

Compare PBH with

PBH vs PARRPBH vs FTIPBH vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer